Joint Venture Proton Therapy Center Under Development
By MedImaging International staff writers
Posted on 27 Feb 2012
A cancer treatment-center project, now under development in the US state of Arizona, is the latest of an ongoing effort to bring cutting-edge treatment technologies to more patients through joint-venture partnerships with physicians and hospitals. Posted on 27 Feb 2012
Proton therapy is a groundbreaking cancer treatment that targets tumors with a beam of protons. By delivering doses with pinpoint precision, proton therapy is painless, non-invasive, and very effective in treating tumors while minimizing damage to surrounding healthy tissue.
Accelitech, LLC (Rosemont, IL, USA), a developer and manager of full-cycle management of technology-driven cancer treatment programs, recently announced its inaugural proton therapy project. Due to the high cost and large scope of developing a proton therapy center, there are only a small number of places in the United States where patients can receive the treatment. With recent lower cost options entering the market, Accelitech hopes to change that by using its existing model to target several proton therapy locations over the next two years.
“The technology may be new, but our model for success remains the same,” stated Kerwin Brandt, president and CEO of Accelitech. “Proton therapy is the next generation of cancer treatment, and this project is an exciting opportunity to apply our proven, full-cycle management process to making this state-of-the-art technology available to patients on a broader scale.”
Proton beam therapy is a type of external radiotherapy that targets tumors with beams of protons. It has fewer side effects than standard radiation and is proven to be effective in sensitive areas such as the head, spine, and prostate. Because of the exact localization and unique behavior of protons, higher dosages can be delivered with excellent accuracy, sparing more of the healthy tissue that surrounds the tumor. Proton beam therapy is a noninvasive, pain-free procedure that provides a reduced risk of secondary cancer incidents, making it an appealing alternative for the treatment of growing children.
Related Links:
Accelitech